Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • European Hematology Association (EHA) 2024 has been an incredible journey

    European Hematology Association (EHA) 2024 has been an incredible journey! Thank you to all the amazing professionals who made it unforgettable. hashtag#EHA2024 hashtag#Hematology hashtag#ConferenceHighlights hashtag#Research

    2025.02.28
  • European Hematology Association (EHA) 2024 Wrap-Up

    European Hematology Association (EHA) 2024 Wrap-Up: A Confluence of Innovation and Collaboration The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology

    2025.02.28
  • Research Progress丨Analysis of Platinum Intolerance and Treatment Outcomes in First-Line Treatment of Advanced Urothelial Carcinoma Patients

    Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year’s study analyzed data from…

    2025.02.28
  • Insightful Analysis and Future Blueprint: Academician Binghe Xu Highlights COMB, Outlining the Development of Innovative Breast Cancer Drugs in China

    From August 2-4, 2024, the Seventh Tumor Precision Diagnosis and Treatment Conference and the Tenth Breast Cancer Individualized Treatment Conference (COMB), hosted by the China Cancer Foundation and the Beijing Breast Disease Prevention and Treatment Society, were grandly held in Beijing. The conference brought together the latest advancements in individualized precision treatment of breast cancer…

    2025.02.28
  • Celebrating World Breastfeeding Week!

    Celebrating World Breastfeeding Week! From August 1st to 7th, we honor and support the beautiful journey of breastfeeding. Let’s join hands to promote the importance of breastfeeding for both mothers and babies. It’s more than just nourishment—it’s about bonding, health, and giving our little ones the best start in life

    2025.02.28
  • Part 2: Professor Liu Xiufeng on HCC Treatment Advances

    2025.02.28
  • Dr. Chao Sun: Prospects for the Application of Bicyclol – Mechanisms, Therapeutic Significance, and Challenges

    Bicyclol, derived from Schisandra chinensis, has been widely used in the treatment of various liver diseases since its approval by China’s National Medical Products Administration as a hepatoprotective drug. Viral…

    2025.02.28
  • Dr. Xuefeng Luo: In-Depth Analysis of TIPS in the Treatment of Budd-Chiari Syndrome

    Overview of the Study BCS is a rare vascular disorder of the liver, characterized by obstruction of hepatic venous outflow, leading to portal hypertension and hepatic congestion. This potentially life-threatening…

    2025.02.28
«previous next»
Recent Posts
  • CSCO 2026 Debate | Professors Wenyan Chen and Tengfei Chao: Should Immunotherapy Be Combined with Chemotherapy or an ADC in First-Line Treatment of Advanced TNBC?
  • CSCO 2026 | Professor Hong Bu: Standardizing Breast Pathology Diagnosis Requires “Knowing, Understanding, and Applying the Standards,” While Digital and Intelligent Transformation Must Address Clinical Pain Points
  • CSCO 2026 | Professor Chunfang Hao: ADCs Are Expanding Across the Breast Cancer Treatment Continuum, Advancing From Later Lines to First-Line Therapy and From Monotherapy to Combination Regimens
  • CSCO 2026 | Professor Yanxia Shi: Early Intervention Guided by ctDNA and Dual-Target ADC Innovation Are Reshaping Precision Breast Cancer Treatment
  • CSCO 2026 | Professor Yongmei Yin: OptiTROP-Breast05 Wins the “2026 Innovation Research Award,” as China’s First Homegrown TROP2 ADC Advances First-Line TNBC Treatment
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top